Corey Cutler, MD, MPH, and Hannah Choe, MD, provide an overview of chronic graft-vs-host disease (GVHD) and identify characteristics that differentiate it from acute GVHD.
The FDA has approved neladalkib for TKI-pretreated advanced ALK-positive NSCLC based on ALKOVE-1, requiring only 1 prior line of treatment in those who received prior alectinib.
The designation supports development of onvansertib plus FOLFIRI/bevacizumab as first-line therapy for KRAS- or NRAS-mutated metastatic colorectal cancer, based on phase 2 CRDF-004 findings.
Final PECATI results show a median PFS of 22.1 months and median OS of 40.2 months with lenvatinib plus pembrolizumab in pretreated B3 thymoma and thymic carcinoma.
The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.
During a virtual event, Richard F. Riedel, MD, and participants discussed how monitoring demands, side effects, and patient priorities shape systemic therapy selection after early recurrence of diffuse tenosynovial giant cell tumor.
The approval of pertuzumab-qcay (Pebrilzo) covers metastatic and early-stage HER2-positive breast cancer, but a patent settlement with Genentech delays its earliest US launch until the third quarter of 2028.
Findings from the phase 3 PANOVA-3 trial showed that adding tumor treating fields to gemcitabine and nab-paclitaxel prolonged time to quality-of-life deterioration and improved pain outcomes in unresectable, locally advanced pancreatic cancer.